Use of aldosterone blockade to improve cardiac function in obesity
The University of Queensland
120 participants
Aug 15, 2009
Interventional
Conditions
Summary
Obesity is a risk factor for the development of heart failure. Many apparently well obese subjects have cardiac dysfunction that is detectable with specialized techniques, but which may contribute to the development of heart failure. There are several potential causes for this problem, but fibrosis (scarring) of the heart may be an important one. In this study, we plan to identify whether this can be treated with the aldosterone blocker, spironolactone.
Eligibility
Inclusion Criteria1
- Obesity: Body mass index (BMI) > 30
Exclusion Criteria1
- Diabetes, cardiovascular disease or other chronic disease
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Spironolactone 25mg Oral tablets, once a day for a total of 26 weeks.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12609000655246